

**Table S2. Demographics of patients with wild-type (wt) and mutant (mut) *CDKN2A*.**

		Wt (n = 463)	Mut (n = 139)	<i>P</i>
Median age		57 (19-92)	63 (22-87)	< .001
Female		284 (61.3)	66 (47.5)	.003
Race	Asian	87 (18.8)	28 (20.1)	.70
	Black	19 (4.1)	6 (4.3)	
	Hispanic	74 (16.0)	19 (13.7)	
	White	262 (56.6)	85 (65.1)	
	Others	21 (4.5)	1 (.7)	
PS	0-1	407 (87.9)	115 (82.7)	.28
	2-4	39 (8.4)	17 (12.2)	
	Unknown	17 (3.7)	7 (5.0)	
CCI		1 (0-9)	2 (0-9)	< .001
Treatment	Yes	385 (83.2)	89 (64.0)	< .001
	No	78 (16.8)	50 (36.0)	
Histology	LMS	166 (35.9)	8 (5.8)	< .001
	UPS	100 (21.6)	36 (25.9)	
	LPS	20 (4.3)	58 (41.7)	
	Others	177 (38.2)	37 (26.6)	
<i>TP53</i>	wt	199 (43.0)	107 (77.0)	< .001
	mut	264 (57.0)	32 (23.0)	
<i>RB1</i>	wt	334 (72.1)	137 (98.6)	< .001
	mut	129 (27.9)	2 (1.4)	
<i>PTEN</i>	wt	410 (88.6)	135 (97.1)	.002
	mut	53 (11.4)	4 (2.9)	
<i>ATRX</i>	wt	281 (60.7)	99 (71.2)	< .02
	mut	60 (13.0)	7 (5.0)	
	unknown	122 (26.3)	33 (23.7)	

Note: PS, performance status; CCI, Charlson comorbidity index; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; LPS, liposarcoma. The number inside the parenthesis represents percent except for median age.